As an antioxidant (Jiang et al., 2004), CAT upregulated PKD1-related pathways by increasing the activity of the promoter of the mechanoductive molecule polycystic kidney disease-1 (PKD1), promoted the expression of Sirt1 with strong antioxidant activity, and increased the expression of ALP activity and RUNX 2 in BMSCs under oxidative stress (Zhang et al., 2017), and activation of SIRT 1 can promote angiogenesis and osteogenic differentiation in BMP 9-induced MSCs (Lu et al., 2022). Here, PKD1 is linked to kidney disorder.